A Phase I trial using local regional treatment, nonlethal irradiation, intratumoral and systemic polyinosinic-polycytidylic acid polylysine carboxymethylcellulose to treat liver cancer: in search of the abscopal effect
Open Access
- 1 August 2017
- journal article
- clinical trial-report
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 4, 111-121
Abstract
Purpose: To determine the safety of an approach to immunologically enhance local treatment of hepatocellular cancer (HCC) by combining nonlethal radiation, local regional therapy with intratumoral injection, and systemic administration of a potent Toll-like receptor (TLR) immune adjuvant. Methods: Patients with HCC not eligible for liver transplant or surgery were subject to: 1) 3 fractions of 2-Gy focal nonlethal radiation to increase tumor antigen expression, 2) intra-/peri-tumoral (IT) injection of the TLR3 agonist, polyinosinic-polycytidylic acid polylysine carboxymethylcellulose (poly-ICLC), to induce an immunologic “danger” response in the tumor microenvironment with local regional therapy, and 3) systemic boosting of immunity with intramuscular poly-ICLC. Primary end points were safety and tolerability; secondary end points were progression-free survival (PFS) and overall survival (OS) at 6 months, 1 year, and 2 years. Results: Eighteen patients with HCC not eligible for surgery or liver transplant were treated. Aside from 1 embolization-related severe adverse event, all events were ≤grade II. PFS was 66% at 6 months, 39% at 12 months, and 28% at 24 months. Overall 1-year survival was 69%, and 2-year survival 38%. In patients 60 years (P Conclusion: Intra-tumoral injection of the TLR3 agonist poly-ICLC in patients with HCC is safe and tolerable when combined with local nonlethal radiation and local regional treatment. Further work is in progress to evaluate if this approach improves survival compared to local regional treatment alone and characterize changes in anticancer immunity.Keywords
This publication has 48 references indexed in Scilit:
- Sepsis in cirrhosis: emerging concepts in pathogenesis, diagnosis and managementHepatology International, 2016
- Effect of transcatheter arterial chemoembolization on cellular immune function and regulatory T cells in patients with hepatocellular carcinomaMolecular Medicine Reports, 2015
- Temporal trends in population‐based death rates associated with chronic liver disease and liver cancer in the United States over the last 30 yearsCancer, 2014
- The perspective of immunotherapyCurrent Opinion in Oncology, 2014
- Antigen-presenting cell function in the tolerogenic liver environmentNature Reviews Immunology, 2010
- Changes of CD4+ CD25+ regulatory T cells in peripheral blood in patients with hepatocellular carcinoma before and after TACECurrent Medical Science, 2008
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Unmasking of α-Fetoprotein-Specific CD4+ T Cell Responses in Hepatocellular Carcinoma Patients Undergoing EmbolizationThe Journal of Immunology, 2007
- Increased Populations of Regulatory T Cells in Peripheral Blood of Patients with Hepatocellular CarcinomaCancer Research, 2005
- Association between vascular endothelial growth factor and metastasis after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.2004